Influence of norfloxacin on blood coagulation in children

Keisuke Sunakawa; Takao Yokota; Hironobu Akita; Satoshi Iwata; Yoshitake Sato

doi:10.11250/chemotherapy1953.38.26

Influence of norfloxacin on blood coagulation in children

Keisuke Sunakawa, Takao Yokota, Hironobu Akita, Satoshi Iwata, Yoshitake Sato

Department of Infectious Diseases

Research output: Contribution to journal › Article

Abstract

There have been reports of hemorrhagic manifestations associated with the administration of antibiotics, mainly beta-lactams recently introduced into the market. During the course of a clinical study to assess the safety of a new quinolone, norfloxacin (NFLX) in children, we investigated the drug's influence on blood coagulation and platelet functions. ADP-induced platelet aggregation was measured in seven pediatric patients from 6 months ‘to 10 years’ old being treated with NFLX. The mean values were 51.0±13.1% before administration and 63.8±17.2% during the treatment, showing an improvement in platelet function differing from cases commonly treated with other oral antibacterials. In parallel, tests on blood coagulation and PIVKA II were performed, and no abnormalities caused by NFLX were observed. Our results suggest that NFLX in children has less adverse effect on the normal function of hemostasis and blood coagulation.

Original language	English
Pages (from-to)	26-30
Number of pages	5
Journal	CHEMOTHERAPY
Volume	38
Issue number	1
DOIs	https://doi.org/10.11250/chemotherapy1953.38.26
Publication status	Published - 1990 Jan 1

Fingerprint

Keywords

Norfloxacin

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

Cite this

Sunakawa, K., Yokota, T., Akita, H., Iwata, S., & Sato, Y. (1990). Influence of norfloxacin on blood coagulation in children. CHEMOTHERAPY, 38(1), 26-30. https://doi.org/10.11250/chemotherapy1953.38.26

@article{c9022200bd1e4f8d8d93317fdb1785b4,

title = "Influence of norfloxacin on blood coagulation in children",

abstract = "There have been reports of hemorrhagic manifestations associated with the administration of antibiotics, mainly beta-lactams recently introduced into the market. During the course of a clinical study to assess the safety of a new quinolone, norfloxacin (NFLX) in children, we investigated the drug's influence on blood coagulation and platelet functions. ADP-induced platelet aggregation was measured in seven pediatric patients from 6 months {\textquoteleft}to 10 years{\textquoteright} old being treated with NFLX. The mean values were 51.0±13.1% before administration and 63.8±17.2% during the treatment, showing an improvement in platelet function differing from cases commonly treated with other oral antibacterials. In parallel, tests on blood coagulation and PIVKA II were performed, and no abnormalities caused by NFLX were observed. Our results suggest that NFLX in children has less adverse effect on the normal function of hemostasis and blood coagulation.",

keywords = "Norfloxacin",

author = "Keisuke Sunakawa and Takao Yokota and Hironobu Akita and Satoshi Iwata and Yoshitake Sato",

year = "1990",

month = jan

day = "1",

doi = "10.11250/chemotherapy1953.38.26",

language = "English",

volume = "38",

pages = "26--30",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "1",

}

TY - JOUR

T1 - Influence of norfloxacin on blood coagulation in children

AU - Sunakawa, Keisuke

AU - Yokota, Takao

AU - Akita, Hironobu

AU - Iwata, Satoshi

AU - Sato, Yoshitake

PY - 1990/1/1

Y1 - 1990/1/1

N2 - There have been reports of hemorrhagic manifestations associated with the administration of antibiotics, mainly beta-lactams recently introduced into the market. During the course of a clinical study to assess the safety of a new quinolone, norfloxacin (NFLX) in children, we investigated the drug's influence on blood coagulation and platelet functions. ADP-induced platelet aggregation was measured in seven pediatric patients from 6 months ‘to 10 years’ old being treated with NFLX. The mean values were 51.0±13.1% before administration and 63.8±17.2% during the treatment, showing an improvement in platelet function differing from cases commonly treated with other oral antibacterials. In parallel, tests on blood coagulation and PIVKA II were performed, and no abnormalities caused by NFLX were observed. Our results suggest that NFLX in children has less adverse effect on the normal function of hemostasis and blood coagulation.

AB - There have been reports of hemorrhagic manifestations associated with the administration of antibiotics, mainly beta-lactams recently introduced into the market. During the course of a clinical study to assess the safety of a new quinolone, norfloxacin (NFLX) in children, we investigated the drug's influence on blood coagulation and platelet functions. ADP-induced platelet aggregation was measured in seven pediatric patients from 6 months ‘to 10 years’ old being treated with NFLX. The mean values were 51.0±13.1% before administration and 63.8±17.2% during the treatment, showing an improvement in platelet function differing from cases commonly treated with other oral antibacterials. In parallel, tests on blood coagulation and PIVKA II were performed, and no abnormalities caused by NFLX were observed. Our results suggest that NFLX in children has less adverse effect on the normal function of hemostasis and blood coagulation.

KW - Norfloxacin

UR - http://www.scopus.com/inward/record.url?scp=0025272981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025272981&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.38.26

DO - 10.11250/chemotherapy1953.38.26

M3 - Article

AN - SCOPUS:0025272981

VL - 38

SP - 26

EP - 30

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

IS - 1

ER -

Access to Document

10.11250/chemotherapy1953.38.26